Draft Guidance on Metformin Hydrochloride; Repaglinide

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Metformin hydrochloride; Repaglinide

Dosage Form; Route: Tablet; oral

Recommended Studies: Two studies

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 500 mg; 2 mg
   Subjects: Males and non-pregnant, non-lactating females, general population
   Additional comments: The drug products should be administered with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 minutes for up to 4 hours after dosing.

2. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 500 mg; 2 mg
   Subjects: Males and non-pregnant, non-lactating females, general population
   Additional comments: See comments above

Analytes to measure (in appropriate biological fluid): Metformin and repaglinide in plasma

Bioequivalence based on (90% CI): Metformin and repaglinide

Waiver request of in vivo testing: 500 mg metformin hydrochloride/1 mg repaglinide based on (i) acceptable bioequivalence study on the 500 mg metformin hydrochloride/2 mg repaglinide strength, (ii) proportional similarity of the formulations across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods web site, available to the public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application.